Literature DB >> 26159264

Pathophysiology of Liver Fibrosis.

Massimo Pinzani1.   

Abstract

Progressive accumulation of fibrillar extracellular matrix (ECM) in the liver is the consequence of reiterated liver tissue damage due to infective (mostly hepatitis B and C viruses), toxic/drug-induced, metabolic and autoimmune causes, and the relative chronic activation of the wound-healing reaction. The process may result in clinically evident liver cirrhosis and hepatic failure. Although cirrhosis is the common result of progressive fibrogenesis, there are distinct patterns of fibrotic development related to the underlying disorders causing the fibrosis. These different patterns of fibrogenic evolution are related to different factors and particularly: (1) the topographic localization of tissue damage, (2) the relative concentration of profibrogenic factors and (3) the prevalent profibrogenic mechanism(s). The mechanisms responsible for the fibrogenic evolution of chronic liver diseases can be summarized in three main groups: chronic activation of the wound-healing reaction, oxidative stress-related molecular mechanisms, and the derangement of the so-called 'epithelial-mesenchymal' interaction leading to the generation of reactive cholangiocytes and peribiliary fibrosis. Most of the knowledge on the cell and molecular biology of hepatic fibrosis derives from in vitro studies employing culture of activated hepatic stellate cells isolated from rat, mouse or human liver. It is now evident that other ECM-producing cells, i.e. fibroblasts and myofibroblasts of the portal tract and circulating 'fibrocytes', are likely to contribute to liver fibrosis. More recently, the attention is progressively shifting to the profibrotic microenvironment of the liver with increasing interest for the role of immune cells and specific subsets of macrophages regulating the progression or the regression of fibrosis, the role of intestinal microbiota and the influence of tissue stiffness. Other major areas of development include the role of tissue hypoxia and the establishment of an anaerobic proinflammatory environment and the influence of epigenetic modification in conditioning the progression of fibrosis.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2015        PMID: 26159264     DOI: 10.1159/000374096

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  41 in total

1.  Comparison between ROI-based and volumetric measurements in quantifying heterogeneity of liver stiffness using MR elastography.

Authors:  Roya Rezvani Habibabadi; Pegah Khoshpouri; Maryam Ghadimi; Mohammadreza Shaghaghi; Sanaz Ameli; Bita Hazhirkarzar; Pallavi Pandey; Mounes Aliyari Ghasabeh; Ankur Pandey; Ihab R Kamel
Journal:  Eur Radiol       Date:  2019-11-08       Impact factor: 5.315

Review 2.  Gaining New Biological and Therapeutic Applications into the Liver with 3D In Vitro Liver Models.

Authors:  Sang Woo Lee; Da Jung Jung; Gi Seok Jeong
Journal:  Tissue Eng Regen Med       Date:  2020-03-23       Impact factor: 4.169

3.  MicroRNA Expression in Focal Nodular Hyperplasia in Comparison with Cirrhosis and Hepatocellular Carcinoma.

Authors:  Gábor Lendvai; Tímea Szekerczés; Benedek Gyöngyösi; Krisztina Schlachter; Endre Kontsek; Adrián Pesti; Attila Patonai; Klára Werling; Ilona Kovalszky; Zsuzsa Schaff; András Kiss
Journal:  Pathol Oncol Res       Date:  2018-11-09       Impact factor: 3.201

4.  Establishment and characterization of an immortalized rat hepatic stellate cell line.

Authors:  Tao Li; Xi-Sheng Leng; Ji-Ye Zhu; Fu-Shun Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

Review 5.  Quantitative Elastography Methods in Liver Disease: Current Evidence and Future Directions.

Authors:  Paul Kennedy; Mathilde Wagner; Laurent Castéra; Cheng William Hong; Curtis L Johnson; Claude B Sirlin; Bachir Taouli
Journal:  Radiology       Date:  2018-03       Impact factor: 11.105

Review 6.  The characteristics of activated portal fibroblasts/myofibroblasts in liver fibrosis.

Authors:  Daniel Karin; Yukinori Koyama; David Brenner; Tatiana Kisseleva
Journal:  Differentiation       Date:  2016-08-31       Impact factor: 3.880

7.  Assessment of bone metabolism biomarkers in serum and saliva of cirrhotic patients.

Authors:  Jefferson Rocha Tenório; Nathália Tuany Duarte; Natália Silva Andrade; Mariana Lobo Bergamini; Ana Carolina Mamana; Paulo Henrique Braz-Silva; Karem L Ortega
Journal:  Clin Oral Investig       Date:  2021-09-07       Impact factor: 3.573

8.  The secretin/secretin receptor axis modulates liver fibrosis through changes in transforming growth factor-β1 biliary secretion in mice.

Authors:  Nan Wu; Fanyin Meng; Pietro Invernizzi; Francesca Bernuzzi; Julie Venter; Holly Standeford; Paolo Onori; Marco Marzioni; Domenico Alvaro; Antonio Franchitto; Eugenio Gaudio; Shannon Glaser; Gianfranco Alpini
Journal:  Hepatology       Date:  2016-06-11       Impact factor: 17.425

9.  Cardiac-induced liver deformation as a measure of liver stiffness using dynamic imaging without magnetization tagging-preclinical proof-of-concept, clinical translation, reproducibility and feasibility in patients with cirrhosis.

Authors:  Manil D Chouhan; Heather E Fitzke; Alan Bainbridge; David Atkinson; Steve Halligan; Nathan Davies; Mark F Lythgoe; Rajeshwar P Mookerjee; Alex Menys; Stuart A Taylor
Journal:  Abdom Radiol (NY)       Date:  2021-06-20

10.  Imaging Biomarkers of Hepatic Fibrosis: Reliability and Accuracy of Hepatic Periportal Space Widening and Other Morphologic Features on MRI.

Authors:  Daniel R Ludwig; Tyler J Fraum; David H Ballard; Vamsi R Narra; Anup S Shetty
Journal:  AJR Am J Roentgenol       Date:  2021-03-17       Impact factor: 3.959

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.